Published in Clin Cancer Res on February 01, 2008
Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med (2010) 3.10
The chemokine superfamily revisited. Immunity (2012) 2.83
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev (2013) 2.11
Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol (2011) 1.98
Chemokines in health and disease. Exp Cell Res (2011) 1.69
Chemokines in tumor progression and metastasis. Oncotarget (2013) 1.64
Current concepts of metastasis in melanoma. Expert Rev Dermatol (2008) 1.34
Targeting metastasis. Nat Rev Cancer (2016) 1.26
The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res (2009) 1.18
Surgery for distant melanoma metastasis. Cancer J (2012) 1.03
Decoding melanoma metastasis. Cancers (Basel) (2010) 1.02
Chemokine 25-induced signaling suppresses colon cancer invasion and metastasis. J Clin Invest (2012) 1.01
Cancer models in Caenorhabditis elegans. Dev Dyn (2010) 0.98
Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol (2010) 0.95
Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment. Mediators Inflamm (2014) 0.94
Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. Front Immunol (2015) 0.91
The fine balance of chemokines during disease: trafficking, inflammation, and homeostasis. Methods Mol Biol (2013) 0.87
Acute small bowel obstruction due to intussusception of malignant amelonatic melanoma of the small intestine. BMJ Case Rep (2012) 0.87
CCR9 homes metastatic melanoma cells to the small bowel. Clin Cancer Res (2008) 0.85
Prognostic molecular biomarkers for cutaneous malignant melanoma. J Surg Oncol (2011) 0.82
Paracrine Activation of Chemokine Receptor CCR9 Enhances The Invasiveness of Pancreatic Cancer Cells. Cancer Microenviron (2013) 0.82
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. J Clin Invest (2016) 0.80
Targeting chemokine pathways in esophageal adenocarcinoma. Cell Cycle (2014) 0.79
The importance of microenvironment: the role of CCL8 in metastasis formation of melanoma. Oncotarget (2015) 0.78
Early solitary small bowel metastasis from stage I cutaneous melanoma. Am J Case Rep (2013) 0.77
CCR9 in cancer: oncogenic role and therapeutic targeting. J Hematol Oncol (2016) 0.77
The role of chemoattractant receptors in shaping the tumor microenvironment. Biomed Res Int (2014) 0.77
"Unsteady gait": an uncommon presentation and course of malignant melanoma in terminal ileum-a case report and review of literature. Case Rep Gastrointest Med (2013) 0.77
The CCR9-CCL25 axis mediates melanoma metastasis to the small intestine. Nat Clin Pract Oncol (2008) 0.76
Antitumor effects of a monoclonal antibody to human CCR9 in leukemia cell xenografts. MAbs (2014) 0.76
CCR9-mediated signaling through β-catenin and identification of a novel CCR9 antagonist. Mol Oncol (2015) 0.76
CCR9:CCL25 in melanoma metastatic to small intestine. Curr Oncol Rep (2009) 0.75
Chemokine-Derived Peptides: Novel Antimicrobial and Antineoplasic Agents. Int J Mol Sci (2015) 0.75
Effect of cryopreservation on delineation of immune cell subpopulations in tumor specimens as determinated by multiparametric single cell mass cytometry analysis. BMC Immunol (2017) 0.75
Mucosal Chemokines. J Interferon Cytokine Res (2017) 0.75
Implications of chemokine receptors and inflammatory lipids in cancer. Immunotargets Ther (2013) 0.75
Epigenetic Regulation of KPC1 Ubiquitin Ligase Effects the NF-κB Pathway in Melanoma. Clin Cancer Res (2017) 0.75
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol (2017) 0.75
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer (2002) 17.49
Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature (2003) 7.56
Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med (2005) 5.89
The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol (2000) 4.78
The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res (2003) 3.03
Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J (2004) 2.94
Preparing the "soil": the premetastatic niche. Cancer Res (2006) 2.92
Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res (2006) 2.69
CCL25 mediates the localization of recently activated CD8alphabeta(+) lymphocytes to the small-intestinal mucosa. J Clin Invest (2002) 2.63
Surgery for melanoma metastatic to the gastrointestinal tract. Ann Surg Oncol (1999) 2.61
Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol (2005) 2.41
Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res (2004) 2.31
Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res (2005) 2.28
Primary and metastatic diseases in malignant melanoma of the gastrointestinal tract. Curr Opin Oncol (2000) 2.07
Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol (2006) 2.03
Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene (2003) 1.96
Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg (1996) 1.91
Functional CCR9 expression is associated with small intestinal metastasis. J Invest Dermatol (2004) 1.80
Tumors of the small intestine. Semin Oncol (1988) 1.66
Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res (2001) 1.61
Chemokines in lymphocyte trafficking and intestinal immunity. Microcirculation (2003) 1.60
Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res (2004) 1.60
Radiologic, endoscopic, and surgical considerations of melanoma metastatic to the gastrointestinal tract. Surgery (1984) 1.59
Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol (2004) 1.50
CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res (2004) 1.50
CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology (2001) 1.48
Detection of cancer cells in mesenteric vein and peripheral vessels by measuring telomerase activity in patients with colorectal cancer. Surgery (2003) 1.45
The tumor microenvironment in the post-PAGET era. Cancer Lett (2006) 1.39
Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res (2000) 1.38
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol (2005) 1.37
Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surg Oncol Clin N Am (2001) 1.29
Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res (2005) 1.15
X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling. Clin Cancer Res (2005) 1.07
Expression of CXCR4 is associated with axillary lymph node status in patients with early breast cancer. Breast (2005) 1.07
TECK, an efficacious chemoattractant for human thymocytes, uses GPR-9-6/CCR9 as a specific receptor. Blood (1999) 1.04
Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma. Hum Pathol (2007) 1.03
Molecular mechanisms of metastasis. Cancer Metastasis Rev (2006) 1.00
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med (2006) 15.64
New models of collaboration in genome-wide association studies: the Genetic Association Information Network. Nat Genet (2007) 13.76
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med (2014) 10.69
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol (2011) 7.18
Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat Genet (2008) 6.06
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun (2012) 4.94
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res (2011) 4.70
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med (2015) 4.64
Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol (2006) 4.51
Direct RNA sequencing. Nature (2009) 4.37
Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol (2009) 4.32
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
Cutaneous melanoma. Lancet (2005) 3.94
Quantification of the yeast transcriptome by single-molecule sequencing. Nat Biotechnol (2009) 3.86
Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg (2005) 3.80
Recalibrating Equus evolution using the genome sequence of an early Middle Pleistocene horse. Nature (2013) 3.45
Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol (2012) 3.24
The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol (2010) 3.02
The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol (2004) 2.99
What would you do if you could sequence everything? Nat Biotechnol (2008) 2.89
Virtual terminator nucleotides for next-generation DNA sequencing. Nat Methods (2009) 2.83
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov (2014) 2.74
Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol (2008) 2.69
Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol (2007) 2.62
Nevus/Melanocytoma/Melanoma: an emerging paradigm for classification of melanocytic neoplasms? Arch Pathol Lab Med (2011) 2.60
The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. BMC Biol (2010) 2.59
Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol (2008) 2.53
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res (2012) 2.46
The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol (2005) 2.41
Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol (2005) 2.41
Patterns of lymphatic drainage from the skin in patients with melanoma. J Nucl Med (2003) 2.41
Keystone flap reconstruction of primary melanoma excision defects of the leg-the end of the skin graft? Ann Surg Oncol (2008) 2.36
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg (2007) 2.28
False-negative sentinel node biopsy because of obstruction of lymphatics by metastatic melanoma: the value of ultrasound in conjunction with preoperative lymphoscintigraphy. Melanoma Res (2009) 2.26
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol (2012) 2.17
Increasing tumor thickness is associated with recurrence and poorer survival in patients with Merkel cell carcinoma. Ann Surg Oncol (2012) 2.13
Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol (2010) 2.06
Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res (2004) 2.05
Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem (2010) 2.03
Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. J Clin Oncol (2013) 2.00
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
Improving doctors' letters. Med J Aust (2002) 1.98
Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol (2007) 1.97
Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet (2013) 1.95
Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol (2012) 1.92
Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol (2012) 1.90
BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res (2014) 1.89
True single-molecule DNA sequencing of a pleistocene horse bone. Genome Res (2011) 1.88
The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. Ann Surg Oncol (2008) 1.87
Atypical spitzoid melanocytic tumors with positive sentinel lymph nodes in children and teenagers, and comparison with histologically unambiguous and lethal melanomas. Am J Surg Pathol (2009) 1.82
Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene (2004) 1.81
Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol (2013) 1.80
In vivo confocal microscopy for diagnosis of melanoma and basal cell carcinoma using a two-step method: analysis of 710 consecutive clinically equivocal cases. J Invest Dermatol (2012) 1.79
Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer (2004) 1.78
Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol (2003) 1.78
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res (2009) 1.77
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov (2013) 1.75
Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol (2006) 1.73